Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Digestive Enzyme Capsules is an oral pharmaceutical preparation developed and marketed by Changzhou Qianhong Biopharma for the treatment of indigestion and digestive disorders. The formulation is a combination of several active ingredients: pepsin, pancreatin (containing amylase, lipase, and protease), cellulase, and ursodeoxycholic acid (UDCA). These components work together to supplement endogenous digestive enzymes and bile acids, facilitating the breakdown of proteins, carbohydrates, fats, and plant fibers. Specifically, pepsin and pancreatin proteases degrade proteins, amylase breaks down starches, lipase hydrolyzes fats, and cellulase decomposes cellulose. Ursodeoxycholic acid acts as a choleretic, increasing bile secretion and improving fat emulsification. This product is commonly used to alleviate symptoms such as bloating, loss of appetite, and postprandial discomfort associated with enzyme deficiency or hepatobiliary dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Digestive Enzyme Capsules.